Table 3 Mark-up by other study variables
Variable | Median mark-up (IQR) | p-value | |
|---|---|---|---|
Mark-up strategy | Uses the mark-up strategy | No use of mark-up strategy | |
Cost + fixed percentage | 60 (50–82) | 58(51–85) | 0.050 |
Cost + declining percentage | 55 (50–74) | 61 (50–88) | < 0.001 |
Cost + fixed dispensing fee | 60 (50–81) | 60 (50–83) | 0.421 |
Maximum allowable price | 67 (53–167) | 59 (50–82) | < 0.001 |
Consideration for mark-up | Considered | Not considered | |
Procurement/distribution process | 61 (50–99) | 60 (50–82) | 0.067 |
Market Prices | 62 (50–100) | 59 (50–79) | 0.002 |
Class of drug | 59 (51–86) | 60 (50–82) | 0.429 |
Value of the drug | 60 (50–83) | 60 (50–82) | 0.219 |
Regulation | 65 (52–100) | 59 (50–82) | < 0.001 |
Expiry date | 52 (41–67) | 60 (50–83) | < 0.001 |